The proportion of CLL cells bearing one of the BCL2 mutations varied from 1.4 to 60%, suggesting profound intratumor, other than interpatient, heterogeneity in terms of resistance mechanism [61, 62]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.